First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis by Jianying Lei, Jiahao Zhang, Caicong You, Wu Fu, Maobai Liu, Na Li

Get full text

Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China by Caicong You, Caicong You, Jiahao Zhang, Jiahao Zhang, Jianying Lei, Jianying Lei, Wu Fu, Wu Fu, Bin Zheng, Bin Zheng, Maobai Liu, Maobai Liu, Na Li, Na Li

Get full text

Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States by Caicong You, Jiahao Zhang, Jianying Lei, Wu Fu, Maobai Liu, Hongfu Cai, Bin Zheng, Na Li

Get full text